Conn Harrington

1.3k total citations
10 papers, 266 citations indexed

About

Conn Harrington is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Conn Harrington has authored 10 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Virology and 3 papers in Molecular Biology. Recurrent topics in Conn Harrington's work include HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Conn Harrington is often cited by papers focused on HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Conn Harrington collaborates with scholars based in United States, Belgium and United Kingdom. Conn Harrington's co-authors include Ann M. Saunders, Carl Chiang, Michael C. Irizarry, Marina Zvartau‐Hind, Sharon Sawchak, Maike Gold, J. Davies, C H van Dyck, Andrew Nicholls and Martin T. Lowy and has published in prestigious journals such as Clinical Infectious Diseases, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Conn Harrington

9 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Conn Harrington United States	5	133	81	60	47	43	10	266
Jana Povová Czechia	7	150 1.1×	113 1.4×	51 0.8×	62 1.3×	15 0.3×	10	335
Anahita Zoghi Iran	6	90 0.7×	111 1.4×	29 0.5×	61 1.3×	10 0.2×	10	377
Yu-Chieh Chao China	9	119 0.9×	83 1.0×	41 0.7×	27 0.6×	21 0.5×	13	333
Ana Paula Oliveira Ferreira Brazil	12	64 0.5×	127 1.6×	41 0.7×	58 1.2×	33 0.8×	12	420
Marlena Zyśk Poland	11	159 1.2×	155 1.9×	39 0.7×	68 1.4×	20 0.5×	21	341
Tatiana Shcheglova United States	10	68 0.5×	161 2.0×	91 1.5×	17 0.4×	130 3.0×	17	415
Xue Zhou China	8	221 1.7×	161 2.0×	42 0.7×	141 3.0×	47 1.1×	15	394
Pu‐Yang Sun China	9	205 1.5×	73 0.9×	20 0.3×	110 2.3×	22 0.5×	11	320
Clotilde Bourin United States	7	111 0.8×	64 0.8×	106 1.8×	60 1.3×	14 0.3×	11	250

Countries citing papers authored by Conn Harrington

Since Specialization

Citations

This map shows the geographic impact of Conn Harrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conn Harrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conn Harrington more than expected).

Fields of papers citing papers by Conn Harrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conn Harrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conn Harrington. The network helps show where Conn Harrington may publish in the future.

Co-authorship network of co-authors of Conn Harrington

This figure shows the co-authorship network connecting the top 25 collaborators of Conn Harrington. A scholar is included among the top collaborators of Conn Harrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conn Harrington. Conn Harrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Gutner, Cassidy A., Conn Harrington, Karen Davis, et al.. (2025). P-545. Feasibility, Fidelity, and Effectiveness of Administering CABENUVA in Infusion Centers. Open Forum Infectious Diseases. 12(Supplement_1).

D’Amico, Ronald, Kelong Han, Sherene Min, et al.. (2025). Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS. 39(15). 2182–2190. 1 indexed citations

Ford, Susan L., Franco Felizarta, Kelong Han, et al.. (2025). Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. Clinical Infectious Diseases. 81(1). 101–112. 2 indexed citations

Czarnogorski, Maggie, Paul Benn, Sandy Griffith, et al.. (2022). Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2). 157–161. 2 indexed citations

Talarico, Christine L., Sterling Wu, Marty St. Clair, et al.. (2020). 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. Open Forum Infectious Diseases. 7(Supplement_1). S540–S541. 4 indexed citations

D’Amico, Ronald, Paul Benn, Cynthia McCoig, et al.. (2020). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S847–S848. 2 indexed citations

Cutrell, Amy, Ronald D’Amico, David Dorey, et al.. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases. 6(Supplement_2). S20–S20. 4 indexed citations

Grove, Richard, Conn Harrington, I.J.M. Beresford, et al.. (2014). A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease. Current Alzheimer Research. 11(1). 47–58. 87 indexed citations

Harrington, Conn, Sharon Sawchak, Carl Chiang, et al.. (2011). Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies. Current Alzheimer Research. 8(5). 592–606. 157 indexed citations

10.

Harrington, Conn, Sharon Sawchak, Carl Chiang, et al.. (2009). P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease. Alzheimer s & Dementia. 5(4S_Part_17). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact